Argenx Brings Neuromuscular Leadership To AAN 2026 With New Data Supporting Broader VYVGART Use Across MG And CIDP. <li /> ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results